Geen categorie
1 november 2023
Pan Cancer T’s CEO Rachel Abbott, will participate in the semi finals of the EIT Health Catapult! For more information about the venture challenge see https://eithealth.eu/programmes/catapult/%C2%A0
15 april 2021
Pan Cancer T is awarded with Axon Innovation for Health Award 2021 – selected as the winner out of 21 start-up companies Hilversum, 15 April 2021 […]
3 mei 2023
Dora Hammerl, PCT’s co-founder and VP R&D will present preclinical data on their lead program PCT1 focusing on target and TCR identification. Link to poster: PCT1 […]
11 juli 2024
Rotterdam, July 11 2024 Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 […]
7 februari 2021
Press Release: Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center
Life-saving TCR T-cell therapies for hard-to-treat solid tumors – Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies – Seed investment by Swanbridge Capital and […]
1 september 2021
TCR T cells towards solid tumors: perspective on pitfalls and opportunities Reno Debets, founder and CSO, PCT BV, Rotterdam, the Netherlands Rationale Adoptive T cell […]